摘要
目的:探讨Claudin-1在前列腺癌中的表达状况与前列腺癌临床病理之间的关系。方法:采用组织芯片技术构建包含72例前列腺癌和42例前列腺增生组织的64点阵石蜡组织芯片,利用免疫组化SP法检测该芯片中Claudin-1的表达,探讨其与前列腺癌Gleason评分和临床分期的关系。结果:前列腺癌中,Claudin-1阳性表达率为63.89%(46/72),前列腺增生中表达率33.33%(14/42)(P<0.05);Claudin-1表达与前列腺癌Gleason评分及临床分期相关。结论:Claudin-1表达异常与前列腺癌临床病理特征相关,联合检测可能提高前列腺癌的诊断和预后判断。
Objective: To discuss the expression of Claudin-1 in prostate cancer and the relationship with clinicopathological features of prostate cancer. Methods: Tissue microarray was used to construct a 64-dot matrix paraffin tissue chip containing 72 cases of prostate cancer and 42 cases of benign prostatic hyperplasia. The expression of Claudin-1 in this chip was detected by immunohistochemical SP method. The relationship between the expression of Claudin-1 and gleason score and clinical staging was discussed. Results: The positive rate of Claudin-1 in prostate cancer was 63.89%( 46/72),and that of benign prostatic hyperplasia was 33.33%( 14/42)( P<0.05). The expression of Claudin-1 was correlated with Gleason score and clinical stage of prostate cancer. Conclusion: The abnormal expression of Claudin-1 is correlated with the clinicopathologic features of prostate cancer. Combined detection may be improve the prognosis of prostate cancer.
出处
《转化医学电子杂志》
2018年第2期25-27,共3页
E-Journal of Translational Medicine
基金
浙江省金华市科技局重点科研基金项目(2017-03-016)
